{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:51:53Z","timestamp":1785595913084,"version":"3.56.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.esmoop.2021.100246","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T18:57:02Z","timestamp":1629226622000},"page":"100246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study"],"prefix":"10.1016","volume":"6","author":[{"given":"A.","family":"Raimondi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fuc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.G.","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Antoniotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Smiroldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Amatu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tampellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ritorto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Murialdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Clavarezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Zaniboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Berenato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Corallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Morano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Di Bartolomeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.esmoop.2021.100246_bib1","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100246_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejca.2018.06.024","article-title":"First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: phase II randomised MACRO2 TTD study","volume":"101","author":"Aranda","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2021.100246_bib3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2019.07.006","article-title":"SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer","volume":"119","author":"Munemoto","year":"2019","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100246_bib4","first-page":"170","article-title":"Maintenance therapy with cetuximab every second week in the first-line treatment of metastatic colorectal cancer: the NORDIC-7.5 study by the nordic colorectal cancer biomodulation group","volume":"14","author":"Pfeiffer","year":"2015","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100246_bib5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(14)70106-8","article-title":"Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial","volume":"15","author":"Wasan","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9980","key":"10.1016\/j.esmoop.2021.100246_bib6","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","article-title":"Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group","volume":"385","author":"Simkens","year":"2015","journal-title":"Lancet"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2021.100246_bib7","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/jco.2016.34.4_suppl.647","article-title":"Efficacy and safety of first-line cetuximab\u00a0+ FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study","volume":"34","author":"Van Cutsem","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2021.100246_bib8","first-page":"iv167","article-title":"Impact of baseline age on efficacy and safety of first-line panitumumab (pmab)\u00a0+ FOLFOX4 vs FOLFOX4 treatment","volume":"25","author":"Douillard","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100246_bib9","first-page":"110","article-title":"Impact of sex on chemotherapy toxicity and efficacy among patients with metastatic colorectal cancer: pooled analysis of 5 randomized trials","volume":"18","author":"Abdel-Rahman","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100246_bib10","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2005.03.171","article-title":"Influence of sex on toxicity and treatment outcome in small-cell lung cancer","volume":"23","author":"Singh","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100246_bib11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/157016307781115485","article-title":"Pharmacogenomics of sex difference in chemotherapeutic toxicity","volume":"4","author":"Wang","year":"2007","journal-title":"Curr Drug Discov Technol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2021.100246_bib12","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1200\/JCO.2020.38.15_suppl.4029","article-title":"Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer (CRC): an analysis of 18,339 patients in the ARCAD database","volume":"38","author":"Wagner","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100246_bib13","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jamaoncol.2019.1467","article-title":"Maintenance therapy with panitumumab alone vs panitumumab plus fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial","volume":"5","author":"Pietrantonio","year":"2019","journal-title":"JAMA Oncol"},{"issue":"33","key":"10.1016\/j.esmoop.2021.100246_bib14","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1200\/JCO.19.01254","article-title":"Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy","volume":"37","author":"Morano","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100246_bib15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejca.2020.04.048","article-title":"Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: a pre-specified secondary analysis of the Valentino study","volume":"135","author":"Raimondi","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100246_bib16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jgo.2018.08.002","article-title":"Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG)","volume":"10","author":"Asimakopoulou","year":"2019","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100246_bib17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jgo.2016.01.006","article-title":"A\u00a0review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer","volume":"7","author":"Rosati","year":"2016","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100246_bib18","first-page":"4015","article-title":"Chemotherapy and targeted agents in the treatment of elderly patients with metastatic colorectal cancer","volume":"9","author":"Tuca","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100246_bib19","doi-asserted-by":"crossref","first-page":"e000086","DOI":"10.1136\/esmoopen-2016-000086","article-title":"Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial","volume":"1","author":"Martinelli","year":"2017","journal-title":"ESMO Open"},{"issue":"suppl 8","key":"10.1016\/j.esmoop.2021.100246_bib20","article-title":"Cetuximab and 1st-line chemotherapy in elderly and younger patients with metastatic colorectal cancer (mCRC): a pooled analysis of the CRYSTAL and OPUS studies","volume":"21","author":"Folprecht","year":"2010","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2021.100246_bib21","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1200\/JCO.2020.38.15_suppl.4002","article-title":"First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: the PANDA study","volume":"38","author":"Lonardi","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100246_bib22","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/annonc\/mdz403","article-title":"Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies","volume":"30","author":"Marmorino","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100246_bib23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/onco.13642","article-title":"FOLFOXIRI-bevacizumab or FOLFOX-panitumumab in patients with left-sided RAS\/BRAF wild-type metastatic colorectal cancer: a propensity score-based analysis","volume":"26","author":"Pietrantonio","year":"2021","journal-title":"Oncologist"},{"issue":"24","key":"10.1016\/j.esmoop.2021.100246_bib24","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International society of geriatric oncology consensus on geriatric assessment in older patients with cancer","volume":"32","author":"Wildiers","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100246_bib25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100246_bib26","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1111\/cas.14117","article-title":"Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer","volume":"110","author":"Yamada","year":"2019","journal-title":"Cancer Sci"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100246_bib27","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/cncr.20878","article-title":"Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma","volume":"103","author":"Chansky","year":"2005","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100246_bib28","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.2002.20.6.1491","article-title":"Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer","volume":"20","author":"Sloan","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100246_bib29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000229751","article-title":"Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147","volume":"77","author":"Jatoi","year":"2009","journal-title":"Oncology"},{"issue":"8","key":"10.1016\/j.esmoop.2021.100246_bib30","first-page":"1079","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.esmoop.2021.100246_bib31","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1196\/annals.1386.006","article-title":"Crosstalk between EGFR and extranuclear steroid receptors","volume":"1089","author":"Migliaccio","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.esmoop.2021.100246_bib32","first-page":"3971","article-title":"Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study","volume":"29","author":"Raimondi","year":"2021","journal-title":"Support Care Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921002076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921002076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:26:26Z","timestamp":1761855986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921002076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2059702921002076"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100246","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100246","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100246"}}